AZD9291 80mg oral each day
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR-TKI Resistant Mutation
Conditions
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
Trial Timeline
Dec 1, 2016 → Dec 1, 2019
NCT ID
NCT02972333About AZD9291 80mg oral each day
AZD9291 80mg oral each day is a phase 3 stage product being developed by AstraZeneca for EGFR-TKI Resistant Mutation. The current trial status is unknown. This product is registered under clinical trial identifier NCT02972333. Target conditions include EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02972333 | Phase 3 | UNKNOWN |
Competing Products
1 competing product in EGFR-TKI Resistant Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP8273 Capsules + ASP8273 Capsules A | Astellas Pharma | Phase 2 | 52 |